Introduction
Metabolic syndrome (MS) increases the risk of developing type 2 diabetes and cardiovascular diseases.
In 1988, Reaven postulated insulin resistance as a central event in the pathogenesis of MS.
In healthy people there is a balance between ROS production and antioxidant agents capable of neutralizing ROS, but in patients with MS there is a reduction in antioxidant (endogenous) defenses and a greater increase in ROS
Colombia is rich in fruits and vegetables. An example is
To evaluate the effects of polyphenol-rich fruit consumption on MS components, it is important to consider the characteristics of the population studied, given that epidemiological and clinical studies have recommended different cutoff points or risk values for MS according to gender.
Materials and Methods
Study population
We included a population of 26 men and 26 women with MS. To the authors knowledge no previous studies with
The study was carried out in accordance with the Code of Ethics of the World Medical Association (Declaration of Helsinki) for experiments with humans. The Bioethics Committee for Human Research of the University Research Headquarters of the University of Antioquia approved the study (Act number 17-58-746, 2017). The study was classified as a minimum risk investigation in accordance with the Resolution No. 8430 of the Colombian Ministry of Health.
Experimental design
This was a double blind, crossover design study, lasting 12 weeks, where the effects of agraz and placebo on MS variables, markers of oxidative stress, inflammation, antioxidant capacity, and insulin resistance were compared between men and women. Subjects were recruited from the University of Antioquia, Medellín-Colombia by flyers, massive emails, and voice-to-voice. After the baseline visit to diagnose
In addition, subjects registered their diet (using a food frequency questionnaire) and a 7-day physical activity record at baseline and last week of each period to verify no changes in diet or exercise.
Nectar of agraz and placebo
Agraz fruits were processed and lyophilized as previously described.
Blood sampling
Blood was extracted after 10–12 h of overnight fasting, from the antecubital vein in ethylenediaminetetraacetic acid tubes and in tubes without anticoagulant to obtain serum. The samples were stored at −70°C for subsequent analysis.
Isolation of peripheral blood mononuclear cells
Peripheral blood mononuclear cells were isolated using a density gradient with the Histopaque 1077 reagent (Sigma-Aldrich, St. Louis, MO) as previously described.
Blood pressure
The armband of an automatic BP monitor (Omron, Healthcare, Inc., Bannockburn, IL) was positioned in the right arm at the level of the heart, after 5 min of resting in the sitting position. Two measurements separate by 1 min were made, if the two values were different in >5 mmHg, a third measurement was done, and the average was used for the analysis.
Anthropometric measures
Body weight (kg) was obtained on a calibrated digital scale. The abdominal perimeter was measured in cm at the upper edge of the iliac crest using a flexible (nonelastic) body tape after a normal expiration.
Blood glucose, triglycerides, and high-density lipoprotein cholesterol
These biochemical variables were measured by enzymatic-colorimetric methods using an automated analyzer (SIEMENS Dimension Clinical Chemistry System, Germany).
Insulin and homeostatic model assessment of insulin resistance
Insulin was measured by enzyme-linked immunosorbent assay (ELISA; ADVIA Centaur® CP) using an automated analyzer (SIEMENS Dimension Clinical Chemistry System). Homeostatic model assessment of insulin resistance (HOMA-IR) was calculated with the following formula: HOMAIR = (insulin μUI/mL × glucose mg/dL)/405.
Inflammatory markers
High-sensitive C-reactive protein (hs-CRP) was measured by immunoturbidimetry in an automatic analyzer (SIEMENS Dimension Clinical Chemistry System). Nuclear factor enhancer of the kappa light chains of activated B cells (NFκB) transcription factor was measured by a sandwich ELISA with the NFκB p65 Transcription Factor Assay Kit (ab176648; abcam, USA), which quantifies the p65 fraction in nuclear extracts of mononuclear cells.
Oxidative markers
Thiobarbituric acid reactive substances (TBARS) were determined using the TBARS Assay Kit (Cayman Chemical, USA) by spectrophotometry at 530 nm. The Malondialdehyde (MDA) content of the unknown samples was determined with a standard MDA curve of known concentrations. Results were expressed as μM MDA. Oxidized low-density lipoprotein (oxLDL) was measured using the Human Oxidized LDL ELISA Kit (MDA LDL, Catalog number STA-369) following the manufacturer's instructions (Cell Biolabs, Inc., San Diego, CA).
Total phenols and antioxidant capacity measured by ferric reducing antioxidant power
To eliminate the interference of proteins for these measurements, the participant’ serum was deproteinized following the protocol described by Serafini et al.
Statistical analyses
For the quantitative variables, summary measures were estimated, and for the qualitative variables, measures of absolute and relative frequency were obtained. For the variables with four measurement times, an analysis of variance (ANOVA) of repeated measurements was performed, and for those with two measurements, a two-way ANOVA was used. Both ANOVAs were run with Bonferroni
Results and Discussion
Participants maintained their usual diet and physical activity, and their body weight was constant throughout the study. Adherence to the study was greater than 80% for men and 98% for women. Thus, the following results were not associated with weight loss, changes in the composition (quantity and quality) of the diet, or changes in physical activity.
In the population admitted to the study, 7.7% met five MS criteria, and 17.3% had four criteria. The most prevalent components of MS according to gender were abdominal obesity in women and elevated triglycerides in men, similar to the results reported by other authors.
At the end, 15.4% of men and 26.9% of women finished the study without MS. Systolic blood pressure (SBP), triglycerides, and high-density lipoprotein cholesterol (HDL-c) were the most responsive components. We observed that women responded better and/or have a greater adherence. Other intervention studies have reported that women responded better to changes in diet than men.
The components of the MS were analyzed over time and according to time × treatment and time × treatment × gender interactions. No differences were observed in physical activity and diet between placebo and agraz periods for each gender; however, differences between genders were observed (data no shown). Although no significant differences were found in the interactions, differences were observed over time in variables such as SBP, glucose, and HDL-c levels. For example, a reduction in BP was observed in the entire group (men + women;
Table 1. Effects of Agraz on Metabolic Syndrome Components According to Gender
Parameters | Men | Women | p |
p |
p |
|||
Treatment | Baseline | Final | Baseline | Final | ||||
WC (cm) | Placebo | 106 ± 1.6 | 106 ± 1.8 | 102 ± 1.8 | 102 ± 1.9 | 0.491 | 0.828 | 0.911 |
Agraz | 107 ± 1.7 | 106 ± 1.7 | 102 ± 1.8 | 102 ± 1.9 | ||||
SBP (mmHg) | Placebo | 124 ± 2.1 | 123 ± 1.9 | 118 ± 2.6 | 115 ± 2.5 | 0.017 |
0.982 | 0.629 |
Agraz | 124 ± 2 | 123 ± 1.8 | 118 ± 2.5 | 116 ± 2.3 | ||||
DBP (mmHg) | Placebo | 76 ± 1.5 | 75 ± 1.3 | 76 ± 1.7 | 75 ± 1.6 | 0.001 |
0.605 | 0.418 |
Agraz | 77 ± 1.7 | 75 ± 1.3 | 76 ± 1.7 | 75 ± 1.7 | ||||
Triglycerides (mg/dL) | Placebo | 240 ± 16 | 235 ± 14 | 204 ± 15 | 189 ± 10 | 0.379 | 0.574 | 0.884 |
Agraz | 237 ± 15 | 231 ± 16 | 209 ± 19 | 203 ± 17 | ||||
Glucose (mg/dL) | Placebo | 98 ± 1.5 | 97 ± 1.2 | 93 ± 1.2 | 96 ± 1.7 | 0.049 |
0.994 | 0.058 |
Agraz | 96 ± 1.5 | 98 ± 1.6 | 96 ± 1.6 | 96 ± 1.7 | ||||
HDL-c (mg/dL) | Placebo | 37 ± 1.2 | 39 ± 1.0 | 41 ± 1.1 | 41 ± 1.1 | 0.034 |
0.927 | 0.613 |
Agraz | 37 ± 0.9 | 38 ± 1.2 | 41 ± 1.2 | 41 ± 1.3 |
ANOVA of repeated measurements with multiple comparison Bonferroni test.
*Significance <0.05.
aTime.
bInteraction time × treatment.
cInteraction time × treatment × gender.
ANOVA, analysis of variance; DBP, diastolic blood pressure; HDL-c, high-density lipoprotein cholesterol; SBP, systolic blood pressure; WC, waist circumference.
The concentration of phenols had a tendency to increase after agraz consumption, both in men and women (
Table 2. Effects of Agraz on Antioxidant Capacity and Oxidative and Inflammatory Markers in Men and Women with Metabolic Syndrome
Men | Women | p |
p |
|||
Placebo | Agraz | Placebo | Agraz | |||
Phenols (mg AG/L) | 235 ± 7 | 239 ± 6 | 313 ± 13 | 328 ± 7 | 0.327 | 0.586 |
FRAP (μM Trolox/L) | 696 ± 19 | 696 ± 21 | 632 ± 17 | 640 ± 26 | 0.955 | 0.943 |
NFκB (abs) | 0.12 ± 0.0 | 0.12 ± 0.0 | 0.11 ± 0.0 | 0.11 ± 0.0 | 0.954 | 0.154 |
Insulin (mUI/L) | 27 ± 2 | 25 ± 2.3 | 21 ± 1.9 | 19 ± 1.7 | 0.432 | 0.974 |
HOMA-IR | 6.7 ± 2.9 | 6.6 ± 2.9 | 5 ± 2.4 | 4.6 ± 2 | 0.752 | 0.646 |
hs-CRP (mg/L) | 3.7 ± 0.2 | 3.3 ± 0.2 | 4.5 ± 0.4 | 3.8 ± 0.3 | 0.108 | 0.505 |
TBARS (μM MDA) | 1.2 ± 0.08 | 1.2 ± 0.07 | 0.8 ± 0.06 | 0.8 ± 0.07 | 0.408 | 0.207 |
oxLDL (ng/mL MDA) | 341 ± 33 | 306 ± 32 | 331 ± 23 | 332 ± 23 | 0.652 | 0.376 |
Two-way ANOVA with multiple comparison for Bonferroni test.
aTreatment.
bInteraction treatment × gender.
FRAP, ferric reducing antioxidant power; HOMA-IR, homeostatic model assessment of insulin resistance; MDA, malondialdehyde; oxLDL, oxidized low-density lipoprotein; TBARS, thiobarbituric acid reactive substances.
Another interesting result was the decrease in the oxidative marker oxLDL by 11% in men, when they consumed agraz, compared to women (
It is important to note that insulin levels and insulin resistance measured by HOMA-IR did not show significant (
Regarding the effects of agraz consumption on inflammation markers, hs-CRP levels decreased by 12.1% and 18.4%, in men and women, respectively (
Given the observed increase in the content of total phenols in both genders and the increase in antioxidant capacity in women after agraz consumption, a subgroup analysis was performed evaluating those who responded increasing their total phenol levels and their antioxidant capacity versus those who did not increase these variables after consuming the nectar of agraz. The results showed significant differences between genders for insulin resistance (
FIG. 1. Comparative effects of agraz consumption on insulin resistance between participants who increased versus those with no increase in their phenol content and by gender in both conditions. Two-way ANOVA with diet consumption correction. *
FIG. 2. Comparative effects of agraz consumption on oxLDL concentrations between participants who increased versus not increased their antioxidant capacity (measured by FRAP) and by gender in both conditions. Two-way ANOVA with diet consumption correction. *
When analyzing the response on insulin resistance, differences were observed between men and women who increased their phenol content (
Subgroup analyses also showed that those who increased their antioxidant capacity after consuming agraz presented 29% significantly lower levels of oxLDL compared to those who did not increase their antioxidant capacity (291 ± 18 vs. 375 ± 21;
Conclusions
The dose of agraz provided in this study increased total phenols and antioxidant capacity in the serum of participants with MS. This increase was greater in women than in men. Although there were no statistical differences in the primary variables according to the initial design, as evidenced in
Author Disclosure Statement
The authors have no conflict of interest to declare.
Abbreviations Used
analysis of variance
blood pressure
diastolic blood pressure
enzyme-linked immunosorbent assay
ferric reducing antioxidant power
high-density lipoprotein cholesterol
homeostatic model assessment of insulin resistance
high-sensitive C-reactive protein
malondialdehyde
metabolic syndrome
nuclear factor enhancer of the kappa light chains of activated B cells
oxidized low-density lipoprotein
reactive oxygen species
systolic blood pressure
thiobarbituric acid reactive substances
waist circumference
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
© Yeisson Galvis-Pérez et al., 2020; Published by Mary Ann Liebert, Inc. This Open Access article is distributed under the terms of the Creative Commons License ( http://creativecommons.org/licenses/by/4.0 ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.
Abstract
The metabolic syndrome (MS) is a constellation of related factors that increases the risk of developing cardiovascular diseases.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Research Group of Toxinology, Therapeutic and Food Alternatives, School of Microbiology, Universidad de Antioquia UdeA, Medellín, Colombia
2 Research Group of Physiology and Biochemistry (PHYSIS), School of Nutrition and Dietetics, Universidad de Antioquia UdeA, Medellín, Colombia
3 Department of Nutritional Sciences, University of Connecticut, Storrs, Connecticut, USA